NRD
ALLO icon

Nebula Research & Development’s Allogene Therapeutics ALLO Stock Holding History

Nebula Research & Development’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-115,988
Closed -$518K – 789
2024
Q1 		$518K Sell
115,988
-23,949
-17% -$99.9K 0.11% 343
2023
Q4 		$449K Buy
+139,937
New +$397K 0.14% 282
2023
Q3 		– Sell
-26,900
Closed -$134K – 479
2023
Q2 		$134K Buy
+26,900
New +$145K 0.1% 291

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nebula Research & Development's ALLO Position: Q2 2024 in Review

Nebula Research & Development sold out of Allogene Therapeutics (ALLO) in Q2 2024, closing a stake of 115,988 shares — an estimated $518K sold.

Nebula Research & Development first reported a position in ALLO in Q2 2023 and held it in 3 quarters. The position peaked at $518K in Q1 2024. 174 funds tracked by Wall St. Rank hold ALLO as of Q2 2024.

  • Nebula Research & Development reported no remaining Allogene Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Nebula Research & Development sold 115,988 Allogene Therapeutics shares in Q2 2024, an estimated $518K.
  • Nebula Research & Development first reported a position in Allogene Therapeutics in Q2 2023 and held it in 3 quarters.
  • Nebula Research & Development's Allogene Therapeutics position peaked at $518K in Q1 2024.
  • 174 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2024.

Based on Nebula Research & Development's 13F filing for Q2 2024, filed 14 Aug 2024.